When biopharma innovators evaluate a pharmaceutical formulation development company in India, their priorities extend beyond laboratory infrastructure. They need scientific partners who can resolve poor API solubility, control polymorphic stability, navigate patent landscapes, and secure trouble-free technology transfers into commercial manufacturing.
At KMS Pharma, we combine pharmaceutical domain expertise with modern Quality by Design (QbD) principles. Whether you are developing an innovator molecule requiring fast-tracked proof of concept, a 505(b)(2) repurposing program, or a complex generic demanding tight bioequivalence alignment, our laboratories in India provide the technical rigour to de-risk your development lifecycle.
Why global sponsors partner with Indian formulation development companies
India has evolved from a generic manufacturing hub into an international centre of excellence for contract research and pharmaceutical formulation development. Global sponsors, from emerging US biotechs to multinational brand leaders, rely on Indian CROs and CDMOs to compress development cycles without sacrificing data integrity.
The advantage stems from access to experienced formulation scientists, advanced analytical instrumentation, and mature supply chains for pharmacopeial excipients. Development budgets go significantly further, allowing teams to run broader multi-factor factorial designs and extensive stress studies early in the project rather than cutting corners.
Substantial capital efficiency: High-density experimental designs at a fraction of Western laboratory operational costs.
Deep technical talent: Pharmaceutical scientists skilled in solving complex BCS Class II and IV drug delivery barriers.
Regulatory fluency: Standardized documentation structured around USFDA 21 CFR Part 210/211, EMA, and CDSCO (India) guidelines.
Seamless scale-up ecosystem: Proximity to major pilot and commercial cGMP manufacturing facilities across the Indian subcontinent.
Preformulation testing and API-excipient compatibility
Formulation failure rarely happens by accident; it almost always traces back to uncharacterised material behaviour in early discovery phases. A viable drug delivery vehicle starts with deep profiling of the Active Pharmaceutical Ingredient (API).
Before running bench-scale blending or wet granulation trials, KMS Pharma screens drug-excipient compatibility under accelerated thermal, moisture, and photo-stress environments. We evaluate solid-state stability, hygroscopicity, intrinsic dissolution rates, and pKa behaviour to prevent degradation reactions, polymorphic transitions, or bioavailability drops months down the line.
Solid-State Profiling
PXRD, DSC, and TGA screening to characterise crystal habit, solvates, polymorphs, and amorphous transitions.
Solubility & Permeability
Assessing pH-dependent solubility profiles and bio-relevant media performance for BCS Class II/IV compounds.
Excipient Compatibility
Binary mixture screening and HPLC/UPLC forced degradation tests to prevent chemical and physical interactions.
Material Flow & Density
Carr's Index, Hausner Ratio, and particle size distribution (PSD) analysis to inform direct compression vs granulation paths.
Applying QbD and DoE to eliminate formulation guesswork
Regulatory bodies like the USFDA and EMA expect pharmaceutical quality to be designed into products from day one, not merely inspected into finished batches. The traditional trial-and-error approach to formulation development is both financially risky and prone to filing delays.
KMS Pharma implements a structured Quality by Design (QbD) architecture governed by ICH Q8(R2), Q9, and Q10. We identify the Quality Target Product Profile (QTPP) and isolate Critical Quality Attributes (CQAs) before designing statistical Design of Experiments (DoE) matrices. This establishes an actionable design space where process parameters can safely vary without impacting product efficacy.
Define QTPP & CQAs
Establishing target drug release curves, assay purity limits, hardness, disintegration, and particulate criteria based on clinical and patient requirements.
Risk Assessment (FMEA)
Ranking Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) using Failure Mode and Effects Analysis to focus laboratory resources on high-risk variables.
Statistical Experimentation (DoE)
Running fractional factorial and response surface designs to model multi-variable interactions—such as binder concentration vs compression force vs dissolution profile.
Control Strategy Definition
Establishing validated in-process testing windows and automated control thresholds to guarantee identical batch outcomes across development and production scales.
Specialized dosage form development portfolio
Every delivery route requires distinct rheological, physical, and pharmacological problem-solving. At KMS Pharma, our formulation development scientists in India handle conventional and complex delivery formats:
Direct compression, wet/dry granulation, bilayer tablets, and delayed/extended-release coatings.
Aseptic processing, terminal sterilization, complex suspension injectables, and freeze-drying cycle optimization.
Taste-masked pediatric formulas, rheology-controlled syrups, self-emulsifying drug delivery systems (SEDDS).
Penetration enhancer integration, emulsion stabilization, in-vitro release testing (IVRT), and microemulsions.
Precise osmolarity control, preservative-free unit doses, viscosity enhancement, and non-irritating buffers.
Solid dispersions, hot-melt extrusion (HME), nanomilling, and cyclodextrin complexation for insolubles.
Integrated analytical method development and ICH stability testing
A robust formulation is only as dependable as the analytical methods that verify it. Developing an exceptional prototype means little if your analytical assays cannot detect related substances, trace nitrosamines, or minor dissolution drift over shelf life.
KMS Pharma pairs formulation teams directly with analytical development scientists under one roof. When our formulation bench prototypes a new batch, analytical specialists develop, validate, and transfer stability-indicating methods simultaneously.
Our walk-in and standalone stability chambers cover all ICH climatic zones (Zone I, II, III, IVa, and IVb), supporting real-time, intermediate, accelerated, and photo-stability testing. Every sample is tracked through fully validated LIMS systems to ensure 21 CFR Part 11 electronic record compliance.
Stability-indicating assay & impurity profiling: Validated HPLC, UHPLC, and GC methods for assay, degradation products, and residual solvents.
Discriminatory dissolution development: Biorelevant dissolution method development (FaSSIF/FeSSIF) providing predictive in-vitro in-vivo correlation (IVIVC).
Extractables & Leachables (E&L): Assessing container closure systems, rubber stoppers, and blister foils to safeguard product integrity.
ICH storage conditions: 25°C/60% RH, 30°C/65% RH, 30°C/75% RH, and 40°C/75% RH regimes with continuous telemetry monitoring.
Scale-up and technology transfer without friction
One of the most frequent pitfalls in pharmaceutical R&D is creating a formulation that performs brilliantly in a 500-gram laboratory mixer but fails during a 50-kilogram pilot trial or a 500-kilogram commercial production run.
At KMS Pharma, our formulation strategies are engineered for scale from the earliest feasibility trials. We account for industrial equipment kinematics, shear rates, heat dissipation limits, blending geometries, and compression dwell times before finalizing batch formulas.
Scalability isn't a problem to solve at the end of development; it's a constraint that must govern your formulation choices from day one.
When your project is ready to move into pilot-scale production or commercial cGMP manufacturing facilities, our senior technology transfer engineers generate comprehensive Technology Transfer Protocols (TTP), Master Formula Cards (MFC), in-process sampling grids, and on-site troubleshooting support to ensure right-first-time execution.
Regulatory dossier support for USFDA, EMA, and DCGI submissions
The ultimate benchmark of formulation development is successful dossier approval by health authorities. Whether you are targeting an ANDA filing in the United States, an MAA submission via the Centralised/Decentralised procedure in Europe, or a Form 44 registration with India's CDSCO, documentation must be pristine.
KMS Pharma structures all development reports, analytical method validation summaries, stability reports, and justification of specifications in Common Technical Document (eCTD) Module 3 format.
Description & Composition
Complete qualitative and quantitative composition reports detailing functional excipient grades and rationale.
Pharmaceutical Development
Comprehensive QbD narrative documenting API properties, formulation development evolution, DoE studies, and design space.
Manufacturing Process
Flow diagrams, critical process parameter limits, holding times, and validated pilot scale-up narratives.
Controls & Stability
Release and shelf-life specifications, validation of analytical procedures, and complete ICH stability data packages.
Checklist: Selecting the right formulation partner in India
Choosing an Indian formulation development partner requires validating both scientific depth and operational transparency. Before signing a master services agreement (MSA), ensure your candidate CRO meets these core criteria:
Demonstrated expertise in your specific dosage form: Experience with oral solids does not automatically equate to aseptic fill-finish capability.
Transparent IP governance: Full contractual ownership of all developed formulations, batch records, analytical methods, and generated intellectual property.
Equipped analytical infrastructure: In-house availability of HPLC, GC, dissolution apparatus, and physical testing units to prevent testing bottlenecks.
Clear communication cadence: Bi-weekly technical update calls, structured stage-gate milestones, and direct access to principal scientists.
Proven tech-transfer track record: Demonstrated success delivering commercial-scale batch transfers to client facilities or third-party CMOs.
Accelerate your formulation project with KMS Pharma
Looking to develop a resilient dosage form, overcome solubility barriers, or scale an existing drug formulation? Speak directly with our senior pharmaceutical scientists in India to review your target product profile.
Request Technical Consultation